Replacing Alteplase with Tenecteplase: Is the Time Ripe?
- Author:
Nishita SINGH
1
;
Bijoy K. MENON
;
Adam A. DMYTRIW
;
Robert W. REGENHARDT
;
Joshua A. HIRSCH
;
Aravind GANESH
Author Information
- Publication Type:Review
- From:Journal of Stroke 2023;25(1):72-80
- CountryRepublic of Korea
- Language:English
- Abstract: Thrombolysis for acute ischemic stroke has predominantly been with alteplase for over a quarter of a century. In recent years, with trials showing evidence of higher rates of successful reperfusion, similar safety profile and efficacy of tenecteplase (TNK) as compared to alteplase, TNK has now emerged as another potential choice for thrombolysis in acute ischemic stroke. In this review, we will focus on these recent advances, aiming: (1) to provide a brief overview of thrombolysis in stroke; (2) to provide comparisons between alteplase and TNK for clinical, imaging, and safety outcomes; (3) to focus on key subgroups of interest to understand if there is an advantage of using TNK over alteplase or vice-versa, to review available evidence on role of TNK in intra-arterial thrombolysis, as bridging therapy and in mobile stroke units; and (4) to summarize what to expect in the near future from recently completed trials and propose areas for future research on this evolving topic. We present compelling data from several trials regarding the safety and efficacy of TNK in acute ischemic stroke along with completed yet unpublished trials that will help provide insight into these unanswered questions.
